Effects of MDMA usually begin 30–45 min after oral administration of a 75–150 mg dose with peak effects occurring 60–90 min after ingestion, which start to diminish after 2 h, however lasting up to 8 h (Table 3). The time to maximum concentration (Tmax) is 2 h after oral ingestion of MDMA 50, 75, or 125 mg. The half-life shows little variation after a wide range of doses. After a 50-, 75-, or 125-mg dose, the half-life is 8 h . Other studies found the half-life to be 9.53 h after a 75-mg dose and 9.12 h after a 125-mg dose . The maximum concentration (Cmax) after oral ingestion appears to be dose dependent. A Cmax of 105.6 ng/ml was reported in a single subject who took a 50-mg dose , whereas a Cmax of 330 ng/ml was found in another subject who took MDMA 135 mg . In a group of eight subjects, the Cmax values after ingestion of MDMA 75 mg and 125 mg were 126.5 and 226.3 ng/ml, respectively , whereas in another group of eight subjects, Cmax values of 130.9 and 236.4 ng/ml were obtained after ingestion of MDMA 75 mg and 125 mg, respectively . These studies indicate, that the Cmax exhibits a slightly greater-than-expected increase compared with the increase in dose. According to these observations, and following a usual recreational dose of 100–150 mg, the Cmax should be in the range of 200–300 ng/ml. The area under the concentration-time curve (AUC) data from these studies also suggests nonlinearity. The AUC measured over 24 h after ingestion of a 125-mg dose (2,235.9 µg/l/h) is more than twice the AUC after ingestion of a 75-mg dose (995.4 µg/l/h . Nonlinearity is further supported by other evidence, in which the dose ratio of MDMA was 1:3 (50 mg and 150 mg), whereas the AUC ratio over 24 h after ingestion was greater than 1:10. The authors suggested that the non-renal clearance of MDMA is dose dependent.
- Disseminate Intravascular Coagulation
- Disseminate Intravascular Coagulation
- Neuroleptic Malignant Syndrome
- Malignant Hyperthermia
- MDMA User
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Hiramatsu M, Kumagai Y, Unger SE, Cho AK. Metabolism of methylenedioxymethamphetamine: formation of dihydroxy-methamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther. 1990;25:521–527.
Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine (“Ecstasy”) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994;47:1151–1156.
Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136–145.
Cami J, de la Torre R, Ortuno J, et al. Pharmacokinetics of ecstasy (MDMA) in healthy subjects . Eur J Clin Pharmacol. 1997;52:A168.
Verebey K, Alrazi J, Jaffee JH. The complications of ‘Ecstasy’ (MDMA). JAMA. 1988;259:1649–1650.
Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R. Analysis of 3,4-methylenedioxymeth-amphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol. 1996;20:432–440.
Hiramatsu M, DiStefano EW, Cho AK. Stereochemical differences in the in vivo and in vitro metabolism of MDMA . FASEB. 1989;3:A1035.
Lin LY, Kumagai Y, Cho AK. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol. 1992;5:401–406.
de la Torre R, Farré M, Ortuno J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol. 2000;49:104–109.
Lin LY, DiStefano EW, Schmitz DA, et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos. 1997;25:1059–1064.
Kreth KP, Kovar KA, Schwab M, Zanger UM. Identification of the human cytochrome P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs. Biochem Pharmacol. 2000;59:1563–1571.
Schwab M, Seyringe RE, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet. 1999;353:593–594.
Saunders N. Ecstasy. In: Walder P, editor. Ecstasy und verwandte Designerdrogen. Zürich: Ricco Bilger; 1994. pp. 26–42.
Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352:1751–1752.
Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy” – related drugs. Biochem Pharmacol. 2000;69:1563–1571.
Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157–164.
Dar KJ, McBrien ME. MDMA-induced hyperthermia: report of a fatality and review of current therapy. Inten Care Med. 1996;22:995–996.
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylene-dioxymethamphetamine. Lancet. 1992;340:384–387.
Benowitz NL. Amphetamines. In: Olson KR, editor. Poisoning and drug overdose. Stamford, CT: Appleton & Lange; 1999. pp. 68–70.
Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia. 1992;47:686–687.
Mallick A, Bodenham AR. MDMA-induced hyperthermia: a survivor with an initial body temperature of 42.9°C. J Accid Emerg Med. 1997;14:336–338.
Murthy BVS, Wilkes RG, Roberts NB. Creatine kinase isoform changes following ecstasy overdose. Anaesth Inten Care. 1997;25:156–159.
Hall AP, Lyburn ID, Spears FD, Riley B. An unusual case of Ecstasy poisoning. Inten Care Med. 1996;22:670–671.
Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“Ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology. 1998;19:241–251.
Hall AP. “Ecstasy” and the anaesthetist. Br J Anaesth. 1997;79:697–698.
Schmidt CJ, Black CK, Abbate GM, Taylor VL. MDMA-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85–90.
Olson KR. Comprehensive evaluation and treatment. In: Olson KR, editor. Poisoning and drug overdose. Stamford, CT: Appleton & Lange; 1999. pp. 1–61.
Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627–633.
Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.
Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with “Ecstasy” and “Eve” misuse. J Clin Pathol. 1996;49:149–153.
McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449–454.
Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ. MDMA (“Ecstasy”) and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol. 2002;21:1001–1007.
McCann U, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Drug Saf. 1996;15:107–115.
Ranalli E, Bouton R. Intracerebral haemorrhage associated with ingestion of “Ecstasy” . Eur Neuropsychopharmacol. 1997;7:S263.
Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking “Ecstasy”. BMJ. 1993;307:1399.
Kessel B. Hyponatraemia after ingestion of “Ecstasy” BMJ. 1994;308:414.
Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “Ecstasy” (3,4-MDMA) . Lancet. 1996;347:1052.
Matthai SM, Davidson DC. Cerebral oedema after ingestion of MDMA (“Ecstasy”) and unrestricted intake of water . BMJ. 1996;312:1359.
Henry JA, Fallon JK, Kicman AT, et al. Low-dose MDMA (“Ecstasy”) induces vasopressin secretion . Lancet. 1998;351:1784.
Wilkins B. Cerebral oedema after MDMA (“Ecstasy”) and unrestricted water intake: hyponatraemia must be treated with low water input. BMJ. 1999;313:689–690.
Parr MJA, Low HM, Botterill P. Hyponatremia and death after “Ecstasy” ingestion. Med J Aust. 1997;166:136–137.
Finch E, Sell L, Arnold D. Cerebral oedema after MDMA (“Ecstasy”) and unrestricted water intake: drug workers emphasize that water is not an antidote to drug . BMJ. 1996;313:690.
Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, et al. The effect of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol. 2002;135:649–656.
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ectasy”). Lancet. 1992;340:384–387.
Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454–458.
Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther. 1999;13:129–133.
McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). Br J Psychiatr. 1994;165:391–395.
Hayner GN, McKinney H. MDMA: the dark side of ecstasy. J Psychoactive Drugs. 1986;18:341–347.
Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy ‘Ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend. 2000;60:105–110.
Dowling GP, McDonough ET, Bost RO. ‘Eve’ and ‘Ecstasy’: a report of five deaths associated with the use of MDEA and MDMA. JAMA. 1987;257:1615–1617.
Perrone J. Amphetamines. In: Viccellio P, editor. Emergency toxicology. Philadelphia: Lippincott-Raven; 1998. pp. 899–902.
Rochester JA, Kirchner JT. Ecstasy (3,4-methylene-dioxymethamphetamine): history, neurochemistry, and toxicology. J Am Board Fam Pract. 1999;12:137–142.
Screaton GR, Singer M, Cairns HS, Thrasher A, Sarne RM, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA (“Ecstasy”) abuse . Lancet. 1992;339:677–678.
McKinney PE. Designer drugs. In: Haddad LM, Shannon MW, Winchester JF, editors. Poisoning and drug overdose. Philadelphia: WB Saunders; 1998. pp. 569–580.
Ames D, Wirshing WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome – a possible link. J Am Med Assoc. 1992;268:1505–1506.
Tehan B. Tehan B. Ecstasy and dantrolene . BMJ. 1993;306:146.
Logan AS, Stickle B, O’Keefe N. Survival following “Ecstasy” ingestion with a peak temperature of 42 degrees. Anaesthesia. 1993;48:1017–1018.
Larner AJ. Dantrolene and ‘Ecstasy’ overdose. Anaesthesia. 1993;38:179–180.
Singarajah C, Lavies NG. An overdose of ectasay. A role for dantrolene. Anaesthesia. 1992;47:686–687.
Campkin NTA, Davies UM. Treatment of ‘Ecstasy’ overdose with dantrolene . Anaesthesia. 1993;48:82–83.
Watson JD, Ferguson C, Hinds CJ, Skinner R, Coakley JH. Exceptional heatstroke induced by amphetamine analogues - does dantrolene have a place. Anaesthesia. 1993;48:542–543.
Dowsett RP. Deaths attributed to “Ecstasy” overdose . Med J Aust. 1996;164:700.
Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B. Ecstasy, 3,4-methylenendioxyamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia . J R Soc Med. 1991;84:371.
Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet. 1991;338:1491–1492.
Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med. 1995;333:1267–1272.
Sandyk R. L-dopa induced ‘serotonin syndrome’ in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol. 1986;6:194–195.
Guze BH, Baxter LRJ. The serotonin syndrome: case responsive to propranolol . J Clin Psychopharmacol. 1986;6:119–120.
McDowell DM. MDMA, ketamine, GHB, and the “club drug” scene. In: Galanter M, Kleber HD, editors. Textbook of substance abuse treatment. Washington, DC: American Psychiatric Press; 1999. pp. 295–305.
Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”). Psychopharmacology. 1995;119:247–60.
© 2009 Springer Science + Business Media B.V.
About this chapter
Cite this chapter
Freye, E. (2009). Pharmacokinetics of MDMA. In: Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2448-0_25
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2447-3
Online ISBN: 978-90-481-2448-0